Stephen Brady, Tempest Therapeutics CEO
April 28, 2023 11:25 AM EDTUpdated April 28, 10:22 PM
R&D

Tem­pest Ther­a­peu­tics’ triple com­bo shows promise in first-line liv­er can­cer, stock jumps

Lei Lei Wu

News Reporter

Tem­pest Ther­a­peu­tics said Fri­day morn­ing that its ex­per­i­men­tal liv­er can­cer ther­a­py on top of stan­dard-of-care treat­ments helped shrink tu­mors in more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times